^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    YL-13027

    i
    Other names: YL-13027, YL 13027
    Associations

    News

    Trials
    Company:
    Shanghai YingLi Pharma
    Drug class:
    TGF-β1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    4ms
    A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P1, N=64, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Jun 2024 --> Jan 2024
    Enrollment open • Trial initiation date • Combination therapy • Metastases
    |
    gemcitabine • albumin-bound paclitaxel • YL-13027
    4ms
    A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P1, N=64, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial • Combination therapy • Metastases
    |
    gemcitabine • albumin-bound paclitaxel • YL-13027
    over1year
    Single-cell transcriptome reveals cellular hierarchies and guides p-EMT-targeted trial in skull base chordoma. (PubMed, Cell Discov)
    Encouragingly, YL-13027 attenuated the growth of SBC and achieved stable disease with no serious adverse events, underscoring the clinical potential for the precision treatment of SBC with this therapy. In summary, we conducted the first single-cell RNA sequencing of SBC and identified several targets that could be translated to the treatment of SBC.
    Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    YL-13027
    almost2years
    YL-13027 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=54, Recruiting, Shanghai YingLi Pharmaceutical Co. Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    YL-13027
    over2years
    YL-13027 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=54, Not yet recruiting, Shanghai YingLi Pharmaceutical Co. Ltd.
    New P1 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    YL-13027
    3years
    [VIRTUAL] A phase I study of a TGF-β receptor I kinase inhibitor YL-13027 in patients with advanced solid tumors. (ASCO 2021)
    YL-13027 is well tolerated and further clinical investigation is warranted.
    Clinical • P1 data • IO biomarker
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    TP53 mutation
    |
    YL-13027